Tianjing Bio and ABL Bio will announce the preclinical research data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC (Society of Cancer Immunotherapy) Annual Meeting

2021105 // -- （“”）（：IMAB），、，，

TJ-CD4B/ABL111TJ-L14B/ABL503，T4-1BB，T

TJ-CD4B/ABL111 is an innovative double antibody that simultaneously targets the tumor antigen claudin 18 splice 2 (Claudin 18.

Another dual antibody product, TJ-L14B/ABL503, is an innovative bispecific antibody that simultaneously targets PD-L1 and 4-1BB.

The poster details are as follows:

title

TJ-CD4B (ABL111), a Claudin18.

702

Poster room

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Dr.

TJ-CD4B (ABL111), a Claudin18.

title

title

TJ-CD4B (ABL111), a Claudin18.
2-targeted 4-1BB tumor engager induces potent
tumor-dependent immune response without dose-limiting toxicity in preclinical
studies

TJ-CD4B (ABL111), a Claudin18.
2-targeted 4-1BB tumor engager induces potent
tumor-dependent immune response without dose-limiting toxicity in preclinical
studies

Poster ID #

702

Poster ID #

Poster ID #

702

702

Show location

Poster room

Show location

Show location

Poster room

Poster room

Show time

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Show time

Show time

November 12-14, 2021 7:00-17:00 (US Eastern Time)

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Reporter

Dr.
Wenqing Jiang, Tianjing Biological

Reporter

Reporter

Dr.
Wenqing Jiang, Tianjing Biological

Dr.
Wenqing Jiang, Tianjing Biological

title

ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor
activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T
cells in tumor microenvironment

Poster ID #

892

Show location

Poster room

Show time

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Reporter

Dr.
Gihoon You, ABL Bio

title

ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor
activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T
cells in tumor microenvironment

title

title

ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor
activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T
cells in tumor microenvironment

ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor
activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T
cells in tumor microenvironment

Poster ID #

892

Poster ID #

Poster ID #

892

892

Show location

Poster room

Show location

Show location

Poster room

Poster room

Show time

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Show time

Show time

November 12-14, 2021 7:00-17:00 (US Eastern Time)

November 12-14, 2021 7:00-17:00 (US Eastern Time)

Reporter

Dr.
Gihoon You, ABL Bio

Reporter

Reporter

Dr.
Gihoon You, ABL Bio

Dr.
Gihoon You, ABL Bio

About TJ-CD4B/ABL111

TJ-CD4B/ABL111 was developed in cooperation with ABL Bio of South Korea (Kosdaq stock code: 298380) in South Korea's GEM market.
TJ-CD4B/ABL111 is a highly specific expression that targets multiple cancers, especially gastric cancer and pancreatic cancer.
The innovative bispecific antibody of the tumor antigen claudin 18 splice body 2 (Claudin 18.
2) and the T cell costimulatory molecule 4-1BB
.
TJ-CD4B's unique 4-1BB binding epitope allows it to activate T cells only when it binds to Claudin 18.
2
.
This feature avoids liver toxicity caused by excessive activation of T cells due to the widespread expression of 4-1BB and reduces the risk of systemic immune response
.

About TJ-L14B/ABL503

TJ-L14B/ABL503 is a highly differentiated bispecific antibody based on PD-L1 developed by Tianjing Bio and ABL Bio (Kosdaq stock code: 298380), which can block PD- The L1 signal stimulates the 4-1BB signal and activates T cells to produce an anti-tumor synergistic effect, thereby transforming a "cold" tumor with a weak immune response into a "hot" tumor that is sensitive to PD-(L)1 treatment
.
The double antibody was developed on ABL Bio's "Grabody-T" antibody engineering technology platform, so that it activates 4-1BB only when tumor cells express PD-L1, which can significantly reduce off-target effects
.
Pre-clinical studies have shown that compared to PD-L1 antibody or 4-1BB antibody single-drug or combination therapy, TJ-L14B/ABL503 as a dual-antibody drug exhibits better anti-tumor activity
.

About Tianjing Biological

Tianjing Bio (Nasdaq: IMAB) is an innovative international biotechnology company focusing on the R&D, production and commercialization of differentiated and innovative biological drugs in the field of tumor immunity
.
The company’s mission is to "continuously develop innovative biological drugs and truly change the lives of patients".
Driven by the two-wheeled strategy of "fast product launch" and "rapid proof of concept", the company quickly established itself through diversified models such as independent research and development and global licensing cooperation.
Since then, it has more than 15 innovative drug R&D pipelines with global competitiveness
.
With its leading new drug R&D capabilities and the rapidly advancing GMP production capacity and commercialization layout, the company is rapidly growing from a clinical stage biotechnology company to a comprehensive global biopharmaceutical company covering the entire industry chain.
It is located in Shanghai (headquarters), Beijing, There are offices in Hangzhou, Guangzhou, Lishui, Hong Kong, Maryland, and San Diego, California
.
For more information, please visit http://ir.
i-mabbiopharma.
com  and follow the official accounts of Tianjing Biopharma on LinkedIn, Twitter and WeChat
.

About  ABL Bio

ABL Bio is a biotechnology company based in South Korea, focusing on the development of antibody therapies for tumor immunity and neurodegenerative diseases
.
ABL Bio was established in 2016
.
In 2016 and 2017, it successfully completed the A and B rounds of financing.
In 2018, it completed the C round of 65 million US dollars in financing
.
At present, the company's product ABL001, a bispecific tumor antibody targeting VEGF and DLL4, has entered phase I clinical trials
.
In the field of neurodegenerative diseases, ABL Bio is using its bispecific antibody expertise to develop next-generation new products designed to maximize the penetration and efficacy of the blood-brain barrier
.
The company's fastest-growing product, ABL301, is a bispecific antibody targeting α-synuclein, which can penetrate the blood-brain barrier through receptor-mediated transcytosis and is used to treat Parkinson's
.
ABL Bio has also established a strong R&D team and is actively engaged in the development of Best-in-Class and First-in-Class bispecific antibodies in the field of immuno-oncology treatments
.

Forward-looking statement

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including the results of clinical trials of TJ-CD4B and TJ-L14B, the potential impact of clinical trial data on patients, The progress of TJ-CD4B and TJ-L14B and the expected clinical development plan, pharmaceutical regulatory milestones and commercialization of TJ-CD4B and TJ-L14B by Tianjing Bio and ABL Bio
.
Due to various important factors, actual results may differ materially from forward-looking statements
.
These factors include, but are not limited to, the risks of the following items: Tianjing Bio and ABL Bio's ability to prove the safety and efficacy of their drug candidates; the clinical results of candidate drugs may not support further development or new drug marketing approval; related regulatory agencies The content and time of the decision on the regulatory approval of drug candidates; the ability of the candidate drug (if approved) of Tianjing Bio to obtain commercial success; the ability of Tianjing Bio to obtain and maintain its technology and drug intellectual property protection; Tianjing Bio Relying on third parties for drug development, production and other services; Tianjing Bio’s limited operating history and the ability to obtain further operating funds to complete the development and commercialization of candidate drugs; New Coronavirus for the company’s clinical development, commercial and other business operations Impact; and the various risks discussed more comprehensively in the "Risk Factors" section of Form 20-F in the most recent annual report by Tianjing Bio; Discussion of certainty and other important factors
.
All forward-looking statements are based on the information currently held by Tianjing Biological.
Unless otherwise required by law, Tianjing Biological has no obligation to publicly update or revise any forward-looking statements due to new information, future events or other reasons
.